Adolescents with hereditary angioedema experienced fewer attacks, improved quality of life and treatment satisfaction with lanadelumab, according to a study published in Annals of Allergy, Asthma & Immunology.
Treatment was safe and tolerable as well, Timothy Craig, DO, clinical researcher, allergy, asthma and immunology, departments of medicine, pediatrics and biomedical sciences, Penn State University, and colleagues wrote.
The study included 21 adolescents (mean age, 14.3 years; 47.6% girls) aged 12 to 17 years with type 1 (n = 18; 85.7%) or type 2 hereditary angioedema (HAE). Symptom